The Theranos scandal was one of the largest corporate fraud cases in Silicon Valley history. Elizabeth Holmes founded Theranos in 2003 with the promise that a small, proprietary device called the Edison could diagnose hundreds of diseases from just a few drops of blood taken by a finger prick. That promise attracted nearly $900 million from investors, pushed the company’s valuation to $9 billion, and landed Holmes on magazine covers as a visionary. The problem: the technology never worked as claimed, and the company spent years covering it up.
What Theranos Claimed vs. What It Actually Did
Holmes pitched a future where patients could skip traditional blood draws entirely. A tiny sample collected in a proprietary vial called a “Nanotainer” would be run through the Edison machine, returning results for hundreds of tests faster and cheaper than any existing lab. It was an enormously appealing idea, both to investors and to health systems looking to cut costs.
In reality, the Edison machines did not give accurate results. Of the more than 240 tests Theranos offered at its headquarters, all but 12 were quietly processed on standard commercial lab equipment the company had secretly purchased from other manufacturers. The core technology that justified the company’s existence was, for practical purposes, a prop. Employees who raised concerns internally were silenced or pushed out.
The Walgreens Deal and Patient Harm
Theranos didn’t just mislead investors. It put its unproven technology into real clinical use. In a high-profile partnership with Walgreens, the company opened 40 “Wellness Centers” inside Walgreens stores in Arizona, plus one location in Palo Alto, California, where patients could walk in and get blood tests. These were real people making real medical decisions based on the results they received.
The consequences were serious. Theranos equipment produced inaccurate results on roughly one in ten tests, affecting thousands of patients out of an estimated 890,000 results generated annually. Some patients received false positive results suggesting they had cancer or other serious conditions, causing significant emotional trauma and prompting unnecessary follow-up procedures. Others may have received falsely reassuring results that delayed treatment for conditions they actually had. Treatment decisions made on bad lab data can be dangerous and, in some cases, life-threatening. Walgreens terminated the partnership in June 2016 and shuttered all 40 Arizona locations.
How the Company Built Credibility
One of the most striking aspects of the scandal is how long Theranos avoided scrutiny. A major reason was the composition of its board of directors, which included prominent diplomats, statesmen, and military leaders rather than people with expertise in medical technology or diagnostics. Holmes recruited these figures deliberately to leverage their connections, raise funds, and generate attention. The board functioned as window dressing, lending an aura of legitimacy that discouraged tough questions about the science.
Investors, too, failed to perform basic due diligence. More than $700 million flowed into the company based on unverified and inflated financial projections. The combination of Holmes’s personal charisma, the emotional appeal of the mission (cheaper, less painful blood testing), and the social proof provided by a famous board created an environment where skepticism was treated as a lack of vision.
How the Fraud Unraveled
The unraveling began in 2015, when Wall Street Journal reporter John Carreyrou published a series of investigative articles revealing that Theranos’s technology did not work as advertised and that the company was running most of its tests on conventional machines. Former employees served as key sources, describing a culture of secrecy and intimidation. Carreyrou later expanded his reporting into the book “Bad Blood,” which became a bestseller.
Federal regulators moved in quickly after the reporting. In 2016, the Centers for Medicare and Medicaid Services found severe deficiencies at the company’s Newark, California lab, and Theranos eventually voided tens of thousands of test results. In March 2018, the Securities and Exchange Commission charged Holmes and Theranos president Ramesh “Sunny” Balwani with massive fraud. Holmes settled with the SEC, agreeing to pay a $500,000 penalty, return 18.9 million shares she had obtained during the fraud, give up her super-majority voting control of the company, and accept a 10-year ban from serving as an officer or director of any public company.
Criminal Convictions and Sentencing
The SEC settlement was a civil action. Criminal charges followed. In June 2018, a federal grand jury indicted both Holmes and Balwani on two counts of conspiracy to commit wire fraud and ten counts of wire fraud. They were tried separately.
Holmes went to trial first. After a nearly four-month trial, a federal jury convicted her in January 2022 on one count of conspiracy to commit fraud against investors and three counts of wire fraud involving transfers totaling more than $140 million. She was sentenced to 135 months in federal prison, which is 11 years and 3 months, plus three years of supervised release.
Balwani’s trial concluded in July 2022, and the jury convicted him on all counts. His sentence was harsher: 155 months, or 12 years and 11 months, also followed by three years of supervision. The Department of Justice specifically noted that his fraud “jeopardized patient health,” reflecting the fact that Balwani’s conviction encompassed harm to patients, not just investors.
Why the Scandal Still Matters
Theranos exposed deep vulnerabilities in how health technology companies are funded and regulated. A startup making bold medical claims raised nearly $900 million without ever publishing peer-reviewed validation of its core technology. Its board had no relevant scientific expertise. Its retail partners failed to independently verify the accuracy of the tests they were offering to patients. And regulators only intervened after journalists did the work of uncovering the fraud.
The case became a cautionary example for the entire startup ecosystem. It demonstrated that a compelling founder narrative and prestigious backers are not substitutes for scientific evidence, and that in healthcare, the cost of unverified claims is measured in patient safety, not just investor losses.